Navigation Links
Researchers at IRB Barcelona discover a general mechanism that accelerates tumor development
Date:2/24/2013

t which have specific activities in diseased states. "This finding is positive from a therapeutic viewpoint because it means that if you remove CPEB1 from healthy cells, its function can be taken over by any other CPEB protein. In contrast, in tumors only CPEB1 has the capacity to shorten these regions, thus affecting only tumor cells", states Italian researcher Felice Alessio Bava, first author of the paper, and post-doctoral fellow with Mndez's group who, this year, has obtained his doctorate degree through the "la Caixa" International Fellowship Programme. This study provides further evidence of the potential of CPEB proteins as therapeutic targets. In 2011, in a study published in Nature Medicine, Mndez identified that CPEB4 "switches on" hundreds of genes linked to tumor growth. This new study explains that the overexpression of CPEB4 in tumors is because CPEB1 has also "released the brakes that keep CPEB4 at low levels in a healthy tissue". "The fact that these proteins control each other is also advantageous from a therapeutic point of view", asserts Mndez, "because partial inhibition, by a drug, would be amplified, thus allowing tumor cell reprogramming. The amplification should make it easier to find a viable compound".

The lab has developed a system to screen therapeutic molecules for a drug that can inhibit the action of CPEB in tumors while having few secondary effects on healthy cells. "There is no drug currently available that influences the regulation of gene expression at this level. Our findings open up a pioneering therapeutic window. We are optimistic about the potential of CPEB proteins as targets", says Mndez.

The action of CPEB proteins should be considered in the design of other therapeutic strategies

The study published in Nature includes a meticulous genomic analysis of RNA molecules that are processed in different ways depending on whether CPBE1 is present. The study provides a list of between 200 a
'/>"/>

Contact: Snia Armengou
armengou@irbbarcelona.org
34-934-037-255
Institute for Research in Biomedicine (IRB Barcelona)
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Brown University researchers build robotic bat wing
2. Researchers say sunlight yields more efficient carbon dioxide to methanol model
3. Researchers decipher modus operandi of potential Alzheimers drug
4. Stanford researchers develop tool for reading the minds of mice
5. Researchers in Manchester find genetic key to preventing spine tumors
6. When It Comes To Genetic Code, Researchers Prove Optimum Isnt Always Best
7. UTSW researchers identify new enzyme that acts as innate immunity sensor
8. Researchers make racehorses fertile
9. USC researchers find possible genetic clues to organ development, birth defects
10. Researchers discover Achilles heel for lymphoid leukemia
11. Researchers find Asian needle ants displacing other aggressive invaders
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers at IRB Barcelona discover a general mechanism that accelerates tumor development
(Date:11/18/2014)... BOSTON , Nov. 17, 2014   ... HealthCare and EMC collaborate to develop The Partners ... , The Partners Data Lake will allow ... to improve diagnostics, treatment and the lives of ... support research and clinical activities across the Partners ...
(Date:11/18/2014)... YORK , Nov. 18, 2014   ... identity authentication solutions, and MorphoTrust USA ... and services, today announced a strategic partnership to ... enterprise, motor vehicle administration (MVA), airport screening and ... in identity-related solutions, MorphoTrust serves consumers through a ...
(Date:11/12/2014)... , Nov. 12, 2014 Crossmatch™, a leading ... its U.are.U ® fingerprint readers have been deployed ... Central Mexico . The bakery chain ... eliminate payroll issues caused by employees clocking in for ... U.are.U fingerprint readers, Montparnasse relied on paper timecards and ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... by NYU School of Medicine researchers reveals that an especially virulent ... pylori ) isn,t implicated in the overall death rate of the ... cancers. The findings, based a nationwide health survey of nearly 10,000 ... January 9, in the journal Gut . Those individuals ...
... announced the winners of its international travel grants ... at the Pennsylvania Convention Center in Philadelphia, February ... is to foster and initiate further interaction between ... financial difficulties. Recipients of this competitive award ...
... Ph.D., a geneticist and biologist at Fred Hutchinson Cancer Research ... Molecular Biology. Sponsored by Pfizer Inc., the award consists of ... by a young scientist. , She was among 18 honored ... range of fields spanning the physical, biological and social sciences. ...
Cached Biology News:Disappearing bacterium may protect against stroke 2Disappearing bacterium may protect against stroke 3Biophysical Society announces winners of 2013 international travel awards 2Biophysical Society announces winners of 2013 international travel awards 3Biophysical Society announces winners of 2013 international travel awards 4National Academy of Sciences honors geneticist and biologist Sue Biggins 2
(Date:12/19/2014)... iLab Solutions, the global leader in ... Bryant as the new Director of Institutional Implementations and ... These two new leadership positions were created to support ... that iLab continues to meet the needs of its ... iLab has been deployed at over 450 core facilities ...
(Date:12/19/2014)... Dec. 18, 2014  Decision Resources Group finds that ... market will grow moderately through 2023 as the aging ... awareness of dental biomaterials all spur procedure volumes. Growth ... China and India ... procedures within reach for a larger proportion of the ...
(Date:12/17/2014)... 2014 The Activated Carbon Manufacturing ... is why IBISWorld updated its original industry research report. ... from an intensified focus on environmental policy. Over the ... standards for power plants and a range of other ... Industry Analyst Sarah Kahn, “a range of downstream industrial ...
(Date:12/17/2014)... 17, 2014 Ipsen Biopharmaceuticals, Inc., ... ADR: IPSEY), today announced that Somatuline® ... Somatuline®) was approved by the U.S. Food and ... neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, ... disease to improve progression-free survival (PFS). , “The ...
Breaking Biology Technology:iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... Dr. Huda Y. Zoghbi ,  director of the ... Texas Children,s Hospital and Baylor College of ... of The Peter and Patricia Gruber Foundation for her pioneering ... number of devastating neurological disorders, including Rett syndrome, spinocerebellar ataxia ...
... OncoSec Medical Incorporated (OTCBB: ONCS), which is developing ... today reported financial results for the quarter ended April ... Total operating expenses for the three and ... $503,000 as compared to $3,000 and $15,000 for the ...
... GENEVA, Switzerland, June 15, 2011 BioXpress Therapeutics ... monoclonal antibody ( MAb ) biosimilars announced ... at the 2011 BIO International Convention,s One-on-One Partnering ... at the Walter E. Washington Convention Center.   ...
Cached Biology Technology:Baylor College of Medicine and Texas Children's Hospital Neuroscientist Dr. Huda Zoghbi Awarded Gruber Neuroscience Prize 2Baylor College of Medicine and Texas Children's Hospital Neuroscientist Dr. Huda Zoghbi Awarded Gruber Neuroscience Prize 3Baylor College of Medicine and Texas Children's Hospital Neuroscientist Dr. Huda Zoghbi Awarded Gruber Neuroscience Prize 4Baylor College of Medicine and Texas Children's Hospital Neuroscientist Dr. Huda Zoghbi Awarded Gruber Neuroscience Prize 5Baylor College of Medicine and Texas Children's Hospital Neuroscientist Dr. Huda Zoghbi Awarded Gruber Neuroscience Prize 6OncoSec Medical Reports Third Quarter 2011 Financial Results 2OncoSec Medical Reports Third Quarter 2011 Financial Results 3OncoSec Medical Reports Third Quarter 2011 Financial Results 4BioXpress Therapeutics SA to Partner the 2011 BIO International Convention 2
ABCA1 Immunogen: Mouse ABCA1-expressing HeLa stable transfectants. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-rat Dipeptidyl Peptidase IV (DPP IV), CD26, Clone 5E8, Monoclonal Antibody...
JAB1 Immunogen: Synthetic peptide, conjugated to KLH, corresponding to residues S(201) E Y Q T I P L N K I E D F G V(216) of human JAB1. The sequence is identical in mouse and rat. Storage: -...
... used to detect the appearance of AcNPV ... cells as early as 8-24 hours post-infection. ... Titer Kit, which allows determination of baculovirus ... The FastPlax Antibody can also be used ...
Biology Products: